Company Nexien BioPharma, Inc.

NXEN

US65343D1000

Pharmaceuticals

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Pharmaceuticals

Market Closed - OTC Markets Other stock markets 10:25:07 2024-05-13 EDT			5-day change	1st Jan Change
0.0163 ^USD	-28.04%		0.00%	-37.07%

02-20	Nexien BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
2023	Nexien BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	CI

Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.

Managers	Title	Age	Since
Richard Greenberg CEO	Chief Executive Officer	75	14-01-31
Evan Wasoff DFI	Director of Finance/CFO	77	-
Jeremy Reeh CTO	Chief Tech/Sci/R&D Officer	-	18-10-25
Robert Goldfarb COO	Chief Operating Officer	69	-
Frank Manganella PRN	Corporate Officer/Principal	58	18-10-29
Joseph Aceto PRN	Corporate Officer/Principal	66	18-10-29

Members of the board	Title	Age	Since
Lindy Snider BRD	Director/Board Member	64	18-01-25
Richard Greenberg CEO	Chief Executive Officer	75	14-01-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	67,472,196	30,966,703 ( 45.90 %)	0	45.90 %

Name	Equities	%	Valuation
Kanativa USA, Inc. 28.16 %	19,000,000	28.16 %	380 000 $
Richard Greenberg 9.167 %	6,185,193	9.167 %	123 704 $
Evan Wasoff 6.669 %	4,500,000	6.669 %	90 000 $
Alex Wasyl 5.649 %	3,811,500	5.649 %	76 230 $
Robert Goldfarb 3.376 %	2,278,000	3.376 %	45 560 $
Lindy Snider 1.082 %	730,000	1.082 %	14 600 $

Nexien BioPharma, Inc.

4340 East Kentucky Avenue Suite 206

80246, Glendale

+303 495 7583

http://www.nexienbiopharma.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
NEXIEN BIOPHARMA, INC.	-37.07%	1.53M
ELI LILLY AND COMPANY	+29.98%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.52%	361B
MERCK & CO., INC.	+18.59%	329B
ABBVIE INC.	+4.07%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.09%	166B

Other Pharmaceuticals